Replies to post #383375 on Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

as I said- Leo has been yapping about IBD over and over and failed to announce in any meaningful way what happened.

Switching to immed release from delayed release AFTER the phase 1 and after those delayed release PRs- remember them???- is a big deal.

This is a real problem. And Leo hid it. In plain sight?

Not nearly so plain as all his other PRs about the topic.

Right?

It is totally bogus.

[MinnieM]

You inspired me to go back and find the original instance of "modified release oral capsule formulation" in the filings. I found the following in 10-Q filed on 11.16.2020.
https://www.sec.gov/Archives/edgar/data/1355250/000147793220006561/ipix_10q.htm

IBD, Ulcerative Colitis (UC) — Brilacidin is also being developed as a treatment in more extensive forms of IBD, with formulation development plans including oral tablets (or capsules) first aimed for the treatment of ulcerative colitis and then Crohn’s disease.

Initial clinical testing in a Phase 1 single-dose escalation trial was conducted in January 2020, which tested a Brilacidin oral formulation in healthy volunteers to assess targeting colon delivery, dispersion, safety, toleration, and systemic exposure/ pharmacokinetics. Data from the Phase 1 trial (NCT03234465) studying the use of delayed-release tablets of Brilacidin showed the trial met its primary endpoints. In the study, the timed-release formulation of Brilacidin was radiolabeled (with complexed technetium-99m) and evaluated for safety and colonic delivery in 9 healthy volunteers (6 with Brilacidin and 3 placebo). Gamma scintigraphic imaging was used to visualize in vivo performance of the enteric coated delayed release tablets designed to target delivery of Brilacidin (50mg, 100mg, and 200mg) to the colon. For Brilacidin treatments, radiolabel release was observed in the ascending colon for four out of the six subjects and in the terminal ileum for the remaining two. Following release, dispersion of the radiolabel was then observed throughout the colon. Serial blood samples were collected through 24 hours post-dose to assess absorption of oral Brilacidin from the colon. Blood level analysis, using a sensitive limit of quantitation in plasma of 1 ng/mL, demonstrated no quantifiable drug concentrations at any timepoint across treatment cohorts, and appears to show containment of Brilacidin within the target location of the colon when delivered by delayed release tablets. Safety outcomes showed that Brilacidin delayed-release tablets were well tolerated by healthy volunteers across all treatment cohorts with no serious adverse events reported. Of the 9 subjects treated, 2 subjects on Brilacidin and 2 subjects on placebo experienced at least one adverse event. The adverse events were of mild intensity and none were deemed to be related to study treatment.

Our oral program development will be supported by a modified release oral capsule formulation now in development. Regulatory approval will be sought to initiate a proposed placebo-controlled Phase 2 clinical trial in UC patients, targeted to begin in the first half of calendar year 2021 once drug supply is available.

In looking at the dates it appears covid interfered with the timing of the original focus and the company pivoted and covered it in the filings. So, I agree with your statement that

I'm not so sure that it was a complete burial.....if so, it was in a shallow grave.

Covid testing, manufacture of drug for covid trial has been the focus since then. The fastest way to pivot to something meaningful appears to be Brilacidin phase III Oral Mucositis.

I'm fine with that.

Let's hope Brilacidin phase II Covid trial meets endpoints. That would solve a lot of issues. I'd sure like to know one way or the other.